Terns Pharma successfully shifted its focus after its GLP-1 obesity drug showed underwhelming results. By pivoting to its promising oncology asset for chronic myeloid leukemia, the company dramatically increased its value, culminating in a nearly $7 billion acquisition by Merck. This demonstrates the value of decisively abandoning struggling programs for high-potential ones.

Eli Lilly's deal chief revealed that even premium acquisition offers are frequently rebuffed by public biotech companies without negotiation. This highlights a significant valuation gap where biotech boards believe their assets are worth far more than what even well-capitalized buyers like Lilly are willing to pay, stalling potential M&A activity.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Merck cited Cedara's extensive, pre-Phase 3 research on pricing and cost-effectiveness as a key factor in its $10B acquisition. This demonstrates that early-stage biotechs can significantly increase their M&A value by proactively building a robust commercial case alongside their clinical development.

Turns' drug, Turn 701, shows a significant valuation disconnect. Despite demonstrating molecular responses three times better than Novartis's Symblix—a drug with a $4B+ peak sales forecast—Turns' market cap is only 1.2 times that peak sales figure. This superior efficacy in a tough-to-treat population suggests considerable remaining upside for the stock.

Market reaction to M&A is nuanced. Despite four deals, investor sentiment remained low because three targeted private companies and the fourth had a minimal premium. This highlights that for public market investors, the *type* and *premium* of an M&A deal are more important catalysts than the raw deal count.

The adage 'biotech companies are bought, not sold' means an acquisition is typically not the result of a company actively seeking a buyer. As with Portola's sale to Alexion, it is often a fiduciary responsibility to consider an unsolicited offer, even if the internal plan is independent growth.

M&A is often framed as a win, but it can be detrimental to patients. The acquisition of an aggressive, fast-moving biotech by a large pharma company can lead to slowed development timelines and more conservative regulatory strategies, ultimately delaying access to life-saving treatments.

A pivotal moment for Alnylam came when competitor Surna Therapeutics was acquired by Merck for $1.1B. This external validation of the entire RNAi space significantly strengthened investor excitement about Alnylam, making it easier for them to raise capital and secure large partnerships. A rival's success can lift all boats.